DDIT3 and diffuse large B-cell lymphoma: A prospective, single-arm, phase 2 clinical study (n = 28) on newly diagnosed DE-DLBCL patients indicated that after 6 cycles of ZR-CHOP (Zanubrutinib plus R-CHOP) treatment, the response rate was significantly higher compared with DE-DLBCL patients who were previously treated with R-CHOP (85.7% vs 70%).22 Another phase II clinical trial included 8 treatment-naive patients with DEL.